Progenics Drug Patent Portfolio
Progenics owns 1 orange book drug protected by 6 US patents Given below is the list of Progenics's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10947197 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL | 09 Jun, 2037 | Active |
| US11851407 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL | 09 Jun, 2037 | Active |
| US8778305 | PSMA-binding agents and uses thereof | 21 Sep, 2030 | Active |
| US12070513 | PSMA-binding agents and uses thereof | 31 Jul, 2029 | Active |
| US9861713 | PSMA-binding agents and uses thereof | 31 Jul, 2029 | Active |
| US8487129 | Heterodimers of glutamic acid | 07 Nov, 2027 | Active |
Latest Legal Activities on Progenics's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Progenics.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Jul, 2025 | US9861713 |
| Notice of Final Determination -Election Required | 11 Jun, 2025 | US9861713 |
| Notice of Final Determination -Election Required | 11 Jun, 2025 | US8778305 |
| Notice of Final Determination -Election Required | 11 Jun, 2025 | US8487129 |
| Notice of Final Determination -Election Required | 06 Jun, 2025 | US8487129 |
| Notice of Final Determination -Election Required | 06 Jun, 2025 | US8778305 |
| Notice of Final Determination -Election Required | 06 Jun, 2025 | US9861713 |
| FDA Final Eligibility Letter | 20 May, 2025 | US9861713 |
| FDA Final Eligibility Letter | 20 May, 2025 | US8778305 |
| FDA Final Eligibility Letter | 20 May, 2025 | US8487129 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Jan, 2025 | US8487129 |
| Mail Patent eCofC Notification | 19 Nov, 2024 | US12070513 |
| Email Notification | 19 Nov, 2024 | US12070513 |
| Patent eCofC Notification | 19 Nov, 2024 | US12070513 |
| Recordation of Patent eCertificate of Correction | 19 Nov, 2024 | US12070513 |
Progenics Drug Patents' Oppositions Filed in EPO
Progenics drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 23, 2021, by Lewis Silkin Llp. This opposition was filed on patent number EP18150494A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP19214298A | Jan, 2023 | Telix Innovations S.A. | Granted and Under Opposition |
| EP18150494A | Sep, 2021 | Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg | Revoked |
| EP18150494A | Sep, 2021 | POLSERVICE KANCELARIA RZECZNIKOW PATENTOWYCH SP. Z O.O. | Revoked |
| EP18150494A | Sep, 2021 | Lewis Silkin LLP | Revoked |
Progenics's Family Patents
Progenics Drug List
Given below is the complete list of Progenics's drugs and the patents protecting them.
1. Pylarify
Pylarify is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10947197 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
09 Jun, 2037
(11 years from now)
| Active |
| US11851407 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL |
09 Jun, 2037
(11 years from now)
| Active |
| US8778305 | PSMA-binding agents and uses thereof |
21 Sep, 2030
(4 years from now)
| Active |
| US12070513 | PSMA-binding agents and uses thereof |
31 Jul, 2029
(3 years from now)
| Active |
| US9861713 | PSMA-binding agents and uses thereof |
31 Jul, 2029
(3 years from now)
| Active |
| US8487129 | Heterodimers of glutamic acid |
07 Nov, 2027
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pylarify's drug page